Eligi
Med
Base de datos
Seguridad
Sobre EligiMed
Contacto
Contáctenos
Ensayos Clínicos de Urología | EligiMed
Ensayos clínicos
334 ensayos encontrados
Completado
Fase 3
ClinicalTrials.gov
A Multinational, Multicenter, Randomized, Double Blind Study Comparing the Efficacy and Safety of AVE5026 With Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Major Abdominal Surgery
INTERVENTIONAL
Inicio: 1 de abr de 2008
ID: NCT00679588
Completado
Fase 3
ClinicalTrials.gov
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Efficacy and Safety Study of Toremifene Citrate for the Prevention of Prostate Cancer in Men With High Grade Prostatic Intraepithelial Neoplasia (PIN)
INTERVENTIONAL
Inicio: 1 de ene de 2005
ID: NCT00106691
Completado
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Double-Blind, Study to Evaluate the Efficacy and Safety of Cefepime-AAI101 Compared to Piperacillin/Tazobactam in the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis.
INTERVENTIONAL
Inicio: 24 de sept de 2018
ID: NCT03687255
Completado
Fase 3
ClinicalTrials.gov
A Phase 3, Three-Arm, Randomized, Open-Label Study Of Interferon Alfa Alone, CCI-779 Alone, And The Combination Of Interferon Alfa And CCI-779 In First-Line Poor-Prognosis Subjects With Advanced Renal Cell Carcinoma.
INTERVENTIONAL
Inicio: 1 de jul de 2003
ID: NCT00065468
Completado
Fase 3
ClinicalTrials.gov
A Phase 3 Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab vs Placebo in Participants With Localized Renal Cell Carcinoma Who Underwent Radical or Partial Nephrectomy and Who Are at High Risk of Relapse
INTERVENTIONAL
Inicio: 7 de jul de 2017
ID: NCT03138512
Terminado
Fase 2
ClinicalTrials.gov
A Phase 2, Randomized, Open-label Study of Nivolumab or Nivolumab/BMS-986205 Alone or Combined With Intravesical BCG in Participants With BCG-Unresponsive, High-Risk, Non-Muscle Invasive Bladder Cancer
INTERVENTIONAL
Inicio: 2 de ago de 2018
ID: NCT03519256
Completado
Fase 4
ClinicalTrials.gov
A 12-Week, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multicenter Trial In Overactive Bladder Subjects To Confirm The Efficacy Of 8 Mg Fesoterodine Compared To 4 Mg Fesoterodine.
INTERVENTIONAL
Inicio: 1 de may de 2011
ID: NCT01302067
Completado
Fase 3
ClinicalTrials.gov
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Dutasteride 0.5 mg Administered Orally Once Daily for Four Years to Reduce the Risk of Biopsy-Detectable Prostate Cancer
INTERVENTIONAL
Inicio: 1 de mar de 2003
ID: NCT00056407
Completado
Fase 3
ClinicalTrials.gov
A Phase III Trial to Test the Efficacy of ZD4054(Zibotentan), an Endothelin A Receptor Antagonist, Versus Placebo in Patients With Hormone Resistant Prostate Cancer (HRPC) and Bone Metastasis Who Are Pain Free and Mildly Symptomatic.
INTERVENTIONAL
Inicio: 1 de nov de 2007
ID: NCT00554229
Completado
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Double-Blind Study of Nivolumab or Placebo in Combination With Docetaxel, in Men With Metastatic Castration-resistant Prostate Cancer
INTERVENTIONAL
Inicio: 6 de feb de 2020
ID: NCT04100018
Completado
Fase 3
ClinicalTrials.gov
A Phase III, Randomized, Multicenter, Double-Blind, Double Dummy, Parallel Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime Avibactam (CAZ-AVI, Formerly CAZ104) Versus Doripenem Followed by Appropriate Oral Therapy in the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis, With a Gram Negative Pathogen in Hospitalized Adults
INTERVENTIONAL
Inicio: 1 de oct de 2012
ID: NCT01595438
Completado
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Open-Label Study of Nivolumab Combined With Ipilimumab Versus Sunitinib Monotherapy in Subjects With Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma
INTERVENTIONAL
Inicio: 16 de oct de 2014
ID: NCT02231749
Completado
Fase 4
ClinicalTrials.gov
An Open Label, Multi-center Pasireotide Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Pasireotide Study and Are Judged by the Investigator to Benefit From Continued Pasireotide Treatment
INTERVENTIONAL
Inicio: 10 de jun de 2013
ID: NCT01794793
Completado
Fase 3
ClinicalTrials.gov
Phase 3b, Randomized, Open-Label Study Of Bevacizumab + Temsirolimus Vs. Bevacizumab + Interferon-Alfa As First-Line Treatment In Subjects With Advanced Renal Cell Carcinoma
INTERVENTIONAL
Inicio: 1 de abr de 2008
ID: NCT00631371
Anterior
1
...
16
17
Filtros